GGrantIndex
← Leaderboards

Dan Douer

University Of Southern California

$1,774,545
Attributed
$1,774,545
Total exposure
6
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $300K · FY200507
$500K$375K$250K$125K$0
'05
'06
'07

Funding mix

By agency

NIH$1,774,545 · 6

By mechanism

R41$797,566 · 2
M01$538,398 · 3
R21$438,581 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Chemotherapy

Research focus

Neoplasm /Cancer ChemotherapyHuman SubjectClinical ResearchRetinoateAcute Myelogenous LeukemiaAntineoplasticsHuman Therapy EvaluationNeoplasm /Cancer Relapse /RecurrenceDrug Screening /EvaluationNeoplasm /Cancer Nutrition TherapyNutrition Related TagVitamin TherapyMyelogenous LeukemiaLiposomesOxidesArsenicBone MarrowClinical Trial Phase INeoplasm /Cancer Palliative TreatmentClinical Trial Phase IiCombination Cancer TherapyBone Marrow PurgingBone Marrow CellsBack

Grant awards (18)

IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy$197,568
R41 · FY2007 · CA · contact PI
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$187,491
R41 · FY2006 · CA · contact PI
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$112,508
R41 · FY2006 · CA · contact PI
Arsenic Trioxide and Vitamin C in AML$219,375
R21 · FY2005 · CA
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$299,999
R41 · FY2004 · CA
Arsenic Trioxide and Vitamin C in AML$219,206
R21 · FY2004 · CA
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2002 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$0
M01 · FY2002 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$155,764
M01 · FY2001 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$155,764
M01 · FY2001 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2001 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$0
M01 · FY2001 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$155,764
M01 · FY2000 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$35,553
M01 · FY2000 · RR
ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML$35,553
M01 · FY2000 · RR
COMPASSIONATE USE OF ARSENIC TRIOXIDE IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2000 · RR
COMPASSIONATE USE OF ARSENIC TRIOXIDE IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2000 · RR
AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA$0
M01 · FY2000 · RR